BOSTON, MA, October 05, 2026 /24-7PressRelease/ -- Philip Ashton-Rickardt, Managing Director and Chief Scientific Officer at BE Therapeutics, is drawing attention to a challenge that sits at the centre of scientific leadership: knowing when to keep pushing an idea and when new evidence should change the direction.

After more than three decades across academic research, biotech entrepreneurship, and R&D leadership, Ashton-Rickardt has worked in environments where uncertainty is part of the job. His career has included professorships at the University of Chicago and Imperial College London, founding Smith Therapeutics, serving as Chief Scientific Officer at Sigilon Therapeutics, advising companies through Flagship Pioneering, and helping build Halyard Therapeutics and BE Therapeutics.

Across those settings, he has seen how easily commitment to an idea can become attachment to it. "You have to separate attachment to the idea from attachment to the problem," Ashton-Rickardt said. "If the problem is important, there may be several ways to approach it."

That distinction can be especially important in biotechnology, where scientific programmes may evolve as new data emerge. A hypothesis that looked promising at the beginning of a project may need to be adjusted, narrowed, or abandoned entirely.

For Ashton-Rickardt, changing direction does not automatically mean that an earlier idea failed. In many cases, it can mean the team has learned enough to make a better decision.

"Flexibility is important because changing your approach is not necessarily an admission that you failed," he said. "Sometimes it is evidence that you learned something."

Confidence Without Pretending to Know the Future

Ashton-Rickardt believes one of the more difficult parts of scientific leadership is providing direction without creating false certainty.

Researchers, executives, investors, and teams often need decisions before every question has been answered. That creates pressure on leaders to sound more certain than the evidence may justify.

He sees a better approach in being clear about what is known, what remains uncertain, and what would cause a decision to change.

"There is a difference between providing direction and pretending to know the future," Ashton-Rickardt said. "In biotech, there are simply too many unknowns."

Rather than weakening confidence, he believes that kind of transparency can strengthen it. When teams understand that new information is expected to influence decisions, they may be more willing to raise concerns, question assumptions, and share evidence that challenges the current plan.

Why Curiosity Still Matters at the Top

Ashton-Rickardt's views have been shaped by a career that has repeatedly required him to enter unfamiliar territory.

Raised in a working-class family in the UK, he worked his way through university and into academic science before eventually leaving a long-established academic career to return to Boston and start a biotech company.

That transition required him to learn a new operating environment while still drawing on years of scientific experience.

He has since moved between startups, established biotech companies, research organisations, and investment-backed environments. Throughout those changes, he says curiosity has remained one of the most important qualities a leader can keep.

"The people I enjoy working with tend to ask good questions, even when those questions make the project more complicated," Ashton-Rickardt said.

He also believes leaders should be willing to admit what they do not know. In his experience, someone who has thought deeply about an idea does not need to pretend it has no weaknesses.

Instead, strong scientific thinking often shows up in the ability to explain what evidence would change a person's mind.

Building Around the Problem, Not the Ego

Ashton-Rickardt's current work remains focused on engineered cell therapies and approaches to treating neurological and other serious diseases.

At BE Therapeutics, where he serves as Managing Director and Chief Scientific Officer, and at Halyard Therapeutics, where he is a co-founder and Chief Scientific Officer, his work continues to centre on translating complex scientific ideas into programmes that can move forward.

That process, he says, requires conviction, but conviction has to remain connected to evidence.

"The goal is not to prove that your first idea was right," Ashton-Rickardt said. "The goal is to solve an important problem."

For scientists and biotech leaders, that difference can shape everything from how teams run experiments to how companies decide where to invest time and resources.

It can also make scientific organisations more adaptable at a time when new tools, new data, and new therapeutic approaches continue to change what is possible.

About Philip Ashton-Rickardt

Philip Ashton-Rickardt is a biotech entrepreneur, academic immunologist, and R&D leader based in Boston, Massachusetts. He serves as Managing Director and Chief Scientific Officer at BE Therapeutics and is co-founder and Chief Scientific Officer of Halyard Therapeutics.

He earned his BSc from King's College London and his PhD in Molecular Immunology from the University of Edinburgh before completing postdoctoral research at MIT. His career has included faculty positions at the University of Chicago and Imperial College London, as well as leadership roles at Smith Therapeutics, AZTherapies, Sigilon Therapeutics, and Flagship Pioneering.

His work has focused on immunology, engineered cell therapies, neurodegenerative disease, and the development of new therapeutic platforms.

# # #